-
Mashup Score: 113Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients - 1 year(s) ago
Arsenic trioxide (ATO)-based regimens are standard in acute promyelocytic leukemia (APL). ATO-related nephrotoxicity has not been reported. We reviewed APL patients treated with ATO to identify cas…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 108Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission - 1 year(s) ago
Key Points. Inotuzumab ozogamicin was safe and effective in eradicating MRD in patients with B-cell acute lymphoblastic leukemia in complete remission.The MRD c
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%. Elias Jabbour, @FadiHaddad_MD @DrHKantarjian of @MDAndersonNews #Leukemia https://t.co/b3mdxluZ6O @ASH_Hematology #ALL #leusm https://t.co/uFH87FIfGF
-
-
Mashup Score: 105Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission - 1 year(s) ago
Key Points. Inotuzumab ozogamicin was safe and effective in eradicating MRD in patients with B-cell acute lymphoblastic leukemia in complete remission.The MRD c
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%. Elias Jabbour, @FadiHaddad_MD @DrHKantarjian of @MDAndersonNews #Leukemia https://t.co/b3mdxluZ6O @ASH_Hematology #ALL #leusm https://t.co/uFH87FIfGF
-
-
Mashup Score: 3What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia - 1 year(s) ago
Leukemia – What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Failing TKI treatment milestones (ELN, NCCN) not that adverse; may not need to change TKI Rx in most patients Hagop Kantarjian, MD of @MDAndersonNews #Leukemia https://t.co/AfGA2Knn9y @LeukemiaJnl #leusm #CML https://t.co/rf8Dwi94jz
-
-
Mashup Score: 9Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia - 2 year(s) ago
Early mortality is a historical measure of quality of care incorporated into many quality measure algorithms that mostly account for patient co-morbid…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Early Mortality as a Quality Indicator in Frontline VERSUS Salvage Acute Myeloid Leukemia Sasaki, @fravandi1, DiNardo, Welch, @TapKadia, @DrHKantarjian of @MDAndersonNews #Leukemia https://t.co/GH4xQHCez0 @OncologyAdvance #leusm #AML
-
-
Mashup Score: 7
There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highli…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Highlighting start of a new era beyond JAK inhibitor monotherapy in MF: Focus on novel #BCLXL inhibitor combinations | led by @doctorpemm of @MDAnderson #Leukemia in @JournalCancer https://t.co/WyMAMbolnv #mpnsm
-
-
Mashup Score: 17
Leukemia – Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Important, multi-disciplinary, joint pediatric/adult leukemia group effort led by our Drs @CuglievanBranko & @doctorpemm → highlighting new era of research & discovery for #BPDCN in #pediatric and #AYA patients https://t.co/6E9fkTfBE9 @LeukemiaJnl @MDAndersonNews https://t.co/EP8jaBSTU9
-
-
Mashup Score: 7Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023 - PubMed - 2 year(s) ago
The field of blastic plasmacytoid dendritic cell neoplasm (BPDCN) is rapidly evolving. Recent clinical developments in this ultra-rare hematologic malignancy have included the emergence of CD123-targeted therapies as the first generation of specific drugs approved for BPDCN. Despite the clinical imp …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
The field of #BPDCN is rapidly evolving | Our new article by Dr. Pemmaraju @doctorpemm highlights the new era of targeting #CD123 in combinations & beyond @MDAndersonNews @clinadvances https://t.co/sMNtxMkAx9 https://t.co/0dE6LYAg4y
-
-
Mashup Score: 7
Background Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential blinatumomab to low-intensity mini-Hyper-CVD chemotherapy with inotuzumab ozogamicin in this setting. Methods Mini-Hyper-CVD (cyclophosphamide and dexamethasone at 50% dose…
Source: BioMed CentralCategories: Hem/Oncs, Latest HeadlinesTweet-
MiniCVD-INO-BLINA in #ALL salvage new standard of care. OOR 83%; 3-yr OS 40%, 52% when both INO-BLINA used, 49% is S1. Kantarjian @FadiHaddad_MD Jabbour @MDAndersonNews #Leukemia https://t.co/q7yOIthx3b @SN_Oncology #leusm https://t.co/s3IdTyXVs0
-
-
Mashup Score: 9Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation - 2 year(s) ago
Key Points. LIT plus venetoclax is associated with favorable post-transplant outcomes in older adults with AML (2-year OS 72%)Type of induction did not impact p
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
In older pts with #AML, low-intensity therapy + ven followed by SCT 2-year OS of 72% and lower NRM than intensive chemo. LIT + ven induction is good option even for SCT-eligible pts. @NicholasShortMD @MDAndersonNews #Leukemia https://t.co/gdzpppIdf9 #leusm https://t.co/7BRuL3f9zz
-
Arsenic trioxide 0.15 mg/kg without capping (15 mg maximum dose cap) may cause renal damage in obese patients with APL @MDAndersonNews @jenweiying @TapKadia @GBorthakur @MusaYilmazMD @fravandi1 Leukemia & Lymphoma https://t.co/iU04O3Y33q